REGENXBIO Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGNX research report →
Range $18 – $29
Price Chart
About the company
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases.
- CEO
- Curran Simpson
- IPO
- 2015
- Employees
- 371
- HQ
- Rockville, MD, US
Get TickerSpark's AI analysis on RGNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $473.44M
- P/E
- -2.23
- Fwd P/E
- 17.90
- PEG
- 0.08
- P/S
- 3.08
- P/B
- 3.16
- EV/EBITDA
- -3.58
- Div Yield
- 0.00%
- Gross Margin
- 87.54%
- Op Margin
- -95.68%
- Net Margin
- -113.85%
- ROE
- -203.98%
- ROIC
- -36.38%
Latest fiscal year · YoY change
- Revenue
- $170.44M+104.5%
- Gross Profit
- $150.14M+201.7%
- Op Income
- $-161,198,000
- Net Income
- $-193,878,000+14.6%
- EPS
- $-3.76+18.1%
- OCF Growth
- +28.4%
- FCF Growth
- +28.0%
- 52W High
- $16.19
- 52W Low
- $5.46
- 50D MA
- $7.54
- 200D MA
- $8.80
- Beta
- 0.93
- RSI (14)
- 45
- Avg Volume
- 1.39M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
REGENXBIO said it is nearing major readouts and filings for sura-vec in wet AMD and RGX-202 in Duchenne, while ending Q3 with $251 million in cash and runway into late Q4 2027.· November 5, 2026
- Sura-vec pivotal wet AMD data from ATMOSPHERE and ASCENT is expected this quarter, with global regulatory submissions planned for 2027.
- RGX-202 is on track for a full BLA filing in Q1 2027, with potential U.S. approval in the second half of 2027 if accepted and reviewed under accelerated approval.
- Cash, cash equivalents and marketable securities were $251 million at quarter-end, and management said runway extends into late Q4 2027.
- Management emphasized differentiation in Duchenne from its C-terminus construct, manufacturing purity, consistent immunosuppression regimen, and the microdystrophin-to-functional-benefit correlation.
- For wet AMD, management said it expects clinically meaningful treatment-burden reduction in a tough-to-treat population and highlighted payer/reimbursement groundwork already underway.
REGENXBIO ended the third quarter of 2026 with cash, cash equivalents and marketable securities of $251 million, compared with $241 million as of December 31, 2025. The increase reflected a $100 million AbbVie milestone payment in July 2026 and net proceeds of $108 million from a July 2026 public offering; this excludes a $39 million payment received in October 2026 from the Sarepta settlement. Management said cash runway extends into late fourth quarter of 2027 beyond multiple milestones, including wet AMD top-line data, the RGX-202 and sura-vec BLA submissions, and the expected PDUFA date for RGX-202. No revenue, EPS, or gross margin figures were provided on the call.
Curran Simpson struck an upbeat tone, saying REGENXBIO is at “an exciting time” and “on the cusp of multiple potential regulatory approvals” as it prepares for commercialization. He repeatedly framed sura-vec and RGX-202 as potential blockbuster programs and emphasized that the company is making disciplined investment decisions while focusing on late-stage execution. He also highlighted commercial readiness, including more than 500 retina specialists trained and in-house manufacturing progress for RGX-202.
Mitch Chan focused on liquidity and runway, noting quarter-end cash of $251 million versus $241 million at year-end 2025. He attributed the increase to the $100 million AbbVie milestone and $108 million in offering proceeds, partially offset by operating use, and said the balance excludes the $39 million Sarepta settlement received in October 2026. He said the company has runway into late Q4 2027 and also continues to receive ZOLGENSMA royalties in select ex-U.S. territories and ITVISMA royalties in the U.S. and certain ex-U.S. territories.
Analysts focused on RGX-202 filing strategy, FDA feedback on accelerated approval, and how the company’s immunosuppression and functional-data package compares with competitors. Management said it will file the full BLA in Q1 2027 rather than rolling, that this should not change the eventual PDUFA timeline, and that the pre-BLA meeting is meant to clarify whether the package fits accelerated approval. On Duchenne, management stressed the microdystrophin-to-NSAA correlation, consistent safety, and liver-toxicity management. On wet AMD, questions centered on fellow-eye data, payer reception, and treatment-burden expectations; management said fellow-eye treatment is a critical differentiator and that payer discussions appear workable because reimbursement codes are established and durability data support the value proposition.
The call reinforced two near-term value drivers: wet AMD top-line data this quarter and a Q1 2027 full BLA filing for RGX-202. Management described both programs as commercially ready or nearly ready, with favorable operational setup, partner support from AbbVie, and a cash runway long enough to reach several key milestones. The company also pointed to differentiated clinical data in Duchenne, including the reported correlation between microdystrophin and function.
Investors still face clinical and regulatory risk, since sura-vec’s pivotal readout is pending and RGX-202 still needs a successful pre-BLA discussion and FDA acceptance under accelerated approval. Management acknowledged that payer adoption for wet AMD will matter, even if they sounded optimistic about reimbursement mechanics. The Duchenne program also remains dependent on FDA comfort with a small-patient correlation dataset and on confirmation that the safety profile holds up in the final package.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.6%
- Shares Outstanding
- 66.12M
- Float Shares
- 56.63M
of shares held by institutions
177 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for RGNX, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 7.68M | ▲ 1.28M |
| Redmile Group, LLC | 4.37M | 0 |
| Jpmorgan Chase & Co | 3.56M | ▲ 1.35M |
| Vanguard Group Inc | 3.37M | ▲ 36.04K |
| State Street Corp | 3.15M | ▲ 182.16K |
| Vanguard Portfolio Management LLC | 2.65M | ▲ 1.29M |
| Vanguard Capital Management LLC | 2.52M | ▲ 415.43K |
| Morgan Stanley | 1.81M | ▼ 139.00K |
| Geode Capital Management, LLC | 1.58M | ▲ 341.46K |
| Goldman Sachs Group Inc | 1.42M | ▼ 418.01K |
| Aqr Capital Management LLC | 1.38M | ▲ 326.65K |
| Nuveen, LLC | 1.01M | ▲ 267.72K |
Held by 235 ETFs
Biggest fund positions in RGNX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 1, 26 | Malzahn Craig | other | 27,777 |
| Nov 1, 26 | Christmas Patrick J. | other | 34,722 |
| Nov 1, 26 | PAKOLA STEVE | other | 34,722 |
| Nov 1, 26 | Chan Mitchell | other | 24,305 |
| Sep 1, 26 | Malzahn Craig | other | 234 |
| Sep 1, 26 | Chan Mitchell | other | 4,902 |
| Aug 27, 26 | Ciongoli Gregory Austin | buy | 53,407 |
| Aug 25, 26 | Ciongoli Gregory Austin | other | 69,609 |
| Aug 26, 26 | Ciongoli Gregory Austin | buy | 49,196 |
| Aug 25, 26 | Ciongoli Gregory Austin | other | 15,432 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RGNX coverage
Recent articles, reports, and earnings notes.
No research on RGNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RGNX report →REGENXBIO Inc. (RGNX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 13
Regenxbio: 2 Major Catalysts Could Change The Investment Case
seekingalpha.com · Nov 6
REGENXBIO Q3 Earnings Call Highlights
marketbeat.com · Nov 6
REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 5
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
prnewswire.com · Nov 5
Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
zacks.com · Nov 4
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
zacks.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.